LAUREN WILSON: Open Payments
NPI 1871225391 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,463 in 72 payments from 22 companies in 2025. Trend: 2023 $2,390 · 2024 $1,260 · 2025 $1,463
Food & beverage: $1,463
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $212 |
| ABBVIE INC. | 10 | $206 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $185 |
| Amneal Pharmaceuticals LLC | 5 | $116 |
| Novartis Pharmaceuticals Corporation | 4 | $112 |
| Alkermes, Inc. | 3 | $76 |
| ARGENX US, INC. | 3 | $75 |
| Neos Therapeutics, LP | 4 | $69 |
| UCB, Inc. | 2 | $62 |
| Lundbeck LLC | 3 | $61 |
Products named: INGREZZA, CAPLYTA, QULIPTA, CREXONT, KESIMPTA, ARISTADA, Adzenys XR-ODT, VYVGART HYTRULO.
Industry payments across MO — which companies pay providers there.
